Home › Research › Disease mechanisms
Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo
Dominic M. Walsh, Igor V. Klyubin, Julia V. Fadeeva, William K. Cullen, Roger Anwyl, Michael S. Wolfe, Michael J. Rowan, Dennis J. Selkoe. Nature, 2002-04-01
Topic: Brain proteins, microglia and lab models
Plain-language summary
This study examined how natural oligomers of human amyloid beta protein are formed, secreted, and affect synaptic function. The researchers tested cell medium containing these oligomers through cerebral microinjection in rats in vivo. They found that the oligomers markedly inhibited hippocampal long-term potentiation and disrupted synaptic plasticity without needing amyloid fibrils.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Walsh, D. M., Klyubin, I. V., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., et al. (2002). Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature. https://doi.org/10.1038/416535a
Vancouver
Walsh DM, Klyubin IV, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002. doi:10.1038/416535a. PMID: 11932745.
BibTeX
@article{walsh2002-11932745,
author = {Walsh, Dominic M. and Klyubin, Igor V. and Fadeeva, Julia V. and Cullen, William K. and Anwyl, Roger and Wolfe, Michael S. and Rowan, Michael J. and Selkoe, Dennis J.},
title = {{Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo}},
journal = {Nature},
year = {2002},
doi = {10.1038/416535a},
pmid = {11932745},
url = {https://doi.org/10.1038/416535a}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Natural oligomers of human Abeta are formed soon after generation of the peptide within specific intracellular vesicles and are subsequently secreted from the cell.
- Cerebral microinjection of cell medium containing these oligomers and abundant Abeta monomers but no amyloid fibrils markedly inhibited hippocampal long-term potentiation (LTP) in rats in vivo.
- Abeta oligomers, in the absence of monomers and amyloid fibrils, disrupted synaptic plasticity in vivo at concentrations found in human brain and cerebrospinal fluid.
- Treatment of cells with gamma-secretase inhibitors prevented oligomer formation at doses that allowed appreciable monomer production, and such medium no longer disrupted LTP.
Why it matters
Reports that naturally secreted oligomers (small clumps) of amyloid beta protein strongly inhibited long-term potentiation in the hippocampus in vivo.
How this study scored 60/100
Published in a top-tier journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on strength of evidence, so that was left out: it earned 57 of the 95 points we could judge it on, which is 60 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 10 / 10 | Tier 1 — top-tier general journal (Nature) |
| Journal's citation record | 4 / 4 | Nature: journal h-index 1,841 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | — / 5 | No evidence rating recorded — left out of this score |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2002 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 7 / 7 | Cited 4,301 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 165.4 citations a year over 26 year(s) since 2002 |
| Impact for its field and year | 6 / 6 | Cited 96.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 4 / 4 | Cited 277 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Dennis J. Selkoe: h-index 174 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 11932745) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 57 / 95 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 57 of the 95 points we could judge it on is 60 out of 100. |
| Total | 60 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Disease mechanisms from nearby years
Also tagged “tdp-43”
1,150 studies in the library carry the topic tag “tdp-43”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,150 tagged studies.